LXRα presumably promotes the differentiation of human gastric cancer cells via the inhibition of Wnt/β-catenin signaling by reducing the β-catenin expression as well as reducing downstream targets of this pathway, including CD44 and cyclin D1. This evidence concerns the gene NR1H3 and gastric cancer.